The Last Shall be First? The Federal Coordinating Committee for Comparative Effectiveness Research
The Department of Health & Human Services announced the 15 member coordinating committee to oversee the $1.1 billion in new spending on comparative effectiveness research included in the stimulus bill. Here are the members, as presented by HHS in its official announcement March 19. There's no way to know for sure who will have the most impact, but it's a safe bet that you can start at the bottom in this case. Ezekiel Emanuel has emerged as a key health policy advisor in the Obama White House-and his brother is the chief of staff.
Anne C. Haddix, Ph.D.
Chief Policy Officer, Office of
Strategy and Innovation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.